Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris

Inclusion Criteria: * Patients ≥ 18 years (males and females), weight ≥ 45 kg at the time of consent. * Confirmation of PNH diagnosis by flow cytometry evaluation white blood cells (WBCs), with neutrophil, granulocyte and/or monocyte clone size of ≥10%. * Evidence of ongoing hemolysis. * ≥1 pRBC transfusion within 12 months prior to screening. * Anemia (Hemoglobin ≤10.5 g/dL). * Lactate dehydrogenase (LDH) level ≥ 1.5 times the upper limit of normal (xULN) during Screening. * Treatment with Soliris * All patients must be vaccinated prior to dosing with MenACWY Menactra® polysaccharide diphtheria toxoid conjugate vaccination against Neisseria meningitidis serogroups A, C, Y, and W-135 and MenB meningococcal serogroup B vaccine (Bexsero®). If the window of vaccination is short, then patients will be prophylactically treated with appropriate antibiotics. * Willing and able to understand and complete informed consent procedures, including signing and dating the informed consent form (ICF), and comply with the study visit schedule. Exclusion Criteria: * Subjects currently or previously under other complement inhibitor treatments other than Soliris less than 3 months prior to study Day 1 * History of bone marrow, hematopoietic stem cell, or solid organ transplantation * History of splenectomy * Participation in any other investigational drug trial within 5 elimination half-lives of enrollment, or within 30 days, whichever is longer * Participants with known or suspected heredita…